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Homoarginine Supplementation Prevents Left Ventricular
Dilatation and Preserves Systolic Function in a Model of Coronary
Artery Disease
Roman N. Rodionov, MD, PhD; Hoshimjon Begmatov, MBBS; Natalia Jarzebska, MSc; Ketul Patel, MS; Matthew T. Mills, BS; Zulaikha Ghani,
MBBS; Doreen Khakshour, BS; Pankti Tamboli, BS; Mitul N. Patel, BS; Mirette Abdalla, MBBS; Maryann Assaf, MS; Stefan R. Bornstein, MD,
PhD; Jose Luis Millan, PhD; Stefanie M. Bode-B€oger, MD, MPH; Jens Martens-Lobenhoffer, PhD; Norbert Weiss, MD; Olga V. Savinova, PhD
Background-—Homoarginine (hArg) has been shown to be cardioprotective in a model of ischemic heart failure; however, the
mechanism remains unknown. hArg can inhibit tissue-nonspeciﬁc alkaline phosphatase (TNAP), an enzyme that promotes vascular
calciﬁcation. We hypothesized that hArg will exert beneﬁcial effects by reducing calciﬁcation in a mouse model of coronary artery
disease associated with TNAP overexpression and hypercholesterolemia.
Methods and Results-—TNAP was overexpressed in the endothelium in mice homozygous for a low-density lipoprotein receptor
mutation (wicked high cholesterol [WHC] allele). WHC and WHC–endothelial TNAP mice received placebo or hArg supplementation
(14 mg/L in drinking water) starting at 6 weeks of age simultaneously with an atherogenic diet. Outcomes were compared
between the groups after 4 to 5 weeks on treatment. Experiments were performed in males, which presented a study limitation. As
expected, WHC–endothelial TNAP mice on the placebo had increased mortality (median survival 27 days, P<0.0001), increased
coronary calcium and lipids (P<0.01), increased left ventricular end-diastolic diameter (P<0.0001), reduced ejection fraction
(P<0.05), and increased myocardial ﬁbrosis (P<0.0001) compared with WHC mice. Contrary to our hypothesis, hArg neither
inhibited TNAP activity in vivo nor reduced coronary artery calciﬁcation and atherosclerosis in WHC–endothelial TNAP mice;
however, compared with the placebo, hArg prevented left ventricular dilatation (P<0.01), preserved ejection fraction (P<0.05), and
reduced myocardial ﬁbrosis (P<0.001).
Conclusions-—The beneﬁcial effect of hArg supplementation in the setting of calciﬁed coronary artery disease is likely due to its
direct protective actions on the myocardial response to the ischemic injury and not to the inhibition of TNAP activity and
calciﬁcation. ( J Am Heart Assoc. 2019;8:e012486. DOI: 10.1161/JAHA.119.012486.)
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L
-Homoarginine (hArg) is a nonproteinogenic amino acid
homologue of L-arginine that has recently been proposed
as an endogenous protective cardiovascular and metabolic
factor.1 hArg is present in human plasma at levels of 1 to
2 lmol/L2 and is thought to be produced from arginine and L-
lysine by the mitochondrial enzyme arginine:glycine amidino-
transferase, which is primarily expressed in the kidneys, liver,
and pancreas.3,4 hArg is also found in certain plants; however,
the relative contribution of dietary hArg consumption to
circulating hArg levels is still unclear.5,6 There are 3 known
pathways for enzymatic homoarginine catabolism—conver-
sion to homocitrulline and nitric oxide by nitric oxide synthase
(NOS), to lysine by arginase, and to 6-guanidino-2-oxocaproic
acid (GOCA) by alanine:glyoxylate aminotransferase 2
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(AGXT2).7 hArg is also excreted by kidneys in unchanged
form.8
Multiple epidemiological studies have demonstrated an
association of low circulating hArg levels with adverse
outcome and increased mortality in cardiovascular, metabolic,
and renal diseases. hArg levels decline with advancement of
chronic kidney disease and are inversely associated with the
risk of progression to dialysis and mortality.9,10 Low hArg
concentration in plasma is also associated with an increased
risk of stroke and cardiovascular mortality.11-13 In patients
with lower extremity arterial disease, low hArg/ADMA ratio
correlated with a higher cardiovascular mortality and higher
incidence of cardiovascular events.14 In a cohort of partici-
pants with median age of 43 years, higher hArg was
associated with a lower rate of major adverse cardiovascular
events and lower all-cause mortality.15
Several animal studies have tested whether hArg has direct
cardiovascular or metabolic protective effects. Indeed, hArg
supplementation has improved outcomes in mice with low
and normal circulating hArg levels subjected to experimental
stroke and helped to preserve cardiac function in a murine
model of post–myocardial infarction heart failure.12,16 hArg
supplementation also rescued impaired cardiac contractile
function in arginine:glycine amidinotransferase knockout
mice.17 With respect to metabolic changes, hArg supplemen-
tation ameliorated blood glucose levels in mice on a high-fat
diet.18 Taken together, these studies suggest that at least in
some settings hArg may have direct protective properties in
addition to being merely a marker of favorable outcomes.
The possible mechanisms of the hypothesized direct
protective effects of hArg are unclear. hArg is a weak substrate
of nitric oxide synthase and a weak competitive inhibitor of L-
arginine catabolism by arginase.19,20 However, it is unlikely that
small changes in circulating hArg levels, which are associated
with adverse outcomes, would affect the L-arginine/nitric oxide
pathway, taking into account that the plasma concentration of
hArg is about 20 times lower than that of arginine.20,21
Since the initial description of hArg as an noncompetitive
inhibitor of tissue-nonspeciﬁc alkaline phosphatase (TNAP) by
Rufo and Fishman,22 several studies have shown that hArg
can inhibit TNAP in vitro at low millimolar concentrations.23-25
Upregulation of TNAP expression in the endothelium leads to
increased vascular calciﬁcation26 and is associated with
accelerated coronary atherosclerosis and mortality in a
mouse model of familial hypercholesterolemia,24 suggesting
that at least some of the protective effects of hArg may be
mediated by its inhibitory action on TNAP in coronary arteries.
To test this hypothesis, we evaluated the effects of hArg
supplementation in our recently developed mouse model, in
which coronary atherosclerosis was induced by a combination
of factors: a mutation in the LDL receptor gene (the wicked
high cholesterol allele, WHC27), increased vascular calciﬁca-
tion due to endothelium-speciﬁc transgenic overexpression of
TNAP (eTNAP), and an atherogenic diet.24
Surprisingly, and contrary to our hypothesis, hArg did not
inﬂuence TNAP activity in vivo, coronary calciﬁcation, or
atherosclerosis but, rather, protected mice from myocardial
remodeling in this model of ischemic heart disease.
Methods
The authors declare that all supporting data are available
within the article. Unprocessed data (echocardiographic and
histologic images) are available from the corresponding
authors on request.
Ethics Statement
Animal studies were approved by the Institutional Animal Care
and Use Committee (IACUC) of New York Institute of
Technology College of Osteopathic Medicine (Old Westbury,
NY) and complied with the National Institutes of Health
guidelines for humane treatment of laboratory animals. Mice
were euthanized by exsanguination under 5% isoﬂurane
anesthesia before terminal experiments.
Experimental Animals
HprtALPL mice, designed to overexpress human ALPL gene
encoding TNAP in a Cre/lox-dependent manner, were previ-
ously described.28 The ALPL coding sequence with a ﬂoxed
“stop” cassette was integrated into the X-linked hypoxanthine
phosphoribosyltransferase (Hprt) locus.29 These mice were
Clinical Perspective
What Is New?
• In various epidemiologic studies, low homoarginine plasma
levels have been found to be associated with adverse
outcomes in multiple cardiovascular, metabolic, and renal
pathologies; however, the mechanism explaining this is not
known.
• Our ﬁndings demonstrate that dietary homoarginine sup-
plementation improved outcomes in a mouse model of
coronary atherosclerosis and heart failure, most probably
due to protection from myocardial remodeling.
What Are the Clinical Implications?
• Our results imply that patients with heart failure might be a
patient population with especially high chances to beneﬁt
from homoarginine supplementation—a well-tolerated and
nonharmful treatment that can be further tested in clinical
studies.
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backcrossed to the C57BL/6-Ldlrwhc strain, which has carried
a familial hypercholesterolemia mutation in the low-density
lipoprotein receptor (Ldlr) gene for 2 generations (WHC allele,
The Jackson Laboratory, Bar Harbor, ME; Stock No. 005061).
Likewise, B6-Tie2cre mice, which expresses Cre recombinase
under control of the Tie2 gene promoter30 (The Jackson
Laboratory, 008863–B6.Cg-Tg(Tek-cre)1Ywa/J), were crossed
to C57BL/6-Ldlrwhc for 2 generations. Male mice of 2
genotypes (Ldlrwhc;HprtALPL;Tie2creTg/+ and Ldlrwhc;HprtALPL;
Tie2cre+/+) were produced by intercrossing homozygous
Ldlrwhc;HprtALPL females with Ldlrwhc;Tie2cretg/+ males as
previously described.24 Female mice were not used in this
study because of the limitations imposed by random X
chromosome inactivation,31 which was expected to result in a
mosaic expression of ALPL from the X-linked Hprt locus. Mice
overexpressing TNAP in a Tie2cre-speciﬁc manner in endothe-
lial cells are referred to as WHC-eTNAP, and their control
littermates WHC. It is important to note that Tie2cre promoter
is also active in macrophages and other myeloid cells, and it is
plausible that TNAP-expressing macrophages contribute to
vascular calciﬁcation in WHC-eTNAP mice. Animals were fed
Paigen diet containing 1.25% cholesterol and 0.5% cholate
(TD.02028) starting at 6 weeks of age. Data were collected at
baseline and 4 to 5 weeks after induction of atherosclerosis
by an atherogenic diet, which corresponded to the median
survival age of WHC-eTNAP mice. Sixty-ﬁve mice were
enrolled in the study, of which 26 were WHC and 39 WHC-
eTNAP. Of these, 16 WHC mice were assigned to the placebo
treatment, and 10 WHC mice to the hArg arm. Twenty-three
WHC-eTNAP were treated with placebo and 16 with hArg
supplementation.
Supplementation With L-Homoarginine
L-Homoarginine was obtained from Sigma (St. Louis, MO;
H1007) and dissolved at 14 mg/L in drinking tap water.
Supplemented water was provided ad libitum and refreshed
weekly. The same regimen has been used by other groups and
resulted in 3-fold increase in plasma L-homoarginine levels
after 4 weeks.16-18 In humans the supplementation was
performed with 125 mg L-homoarginine/day and after
4 weeks led to 7-fold increase in systemic L-homoarginine
levels.20,32 Both regimens (in humans and in mice) resulted in
the addition of 2 mg hArg/kg body weight.
Echocardiography
A Vivid 7 ultrasound instrument (GE Healthcare, Port Wash-
ington, NY) equipped with an i13L transducer (recommended
for cardiac studies in rodents, 5.9-14.1 MHz) was used in all
experiments. Mice were anesthetized with 0.8% to 1.5%
isoﬂurane, and a mid–left ventricular (LV) short-axis view at
the level of the papillary muscles was obtained in B-mode and
recorded in M-mode. LV diameter, LV posterior, and septal
wall thicknesses in systole and diastole as well as time
intervals were measured and averaged over 3 cardiac cycles
using EchoPAC PC software (GE Healthcare, Port Washington,
NY). Heart rate, fractional shortening, ejection fraction,
cardiac output, and LV mass were calculated using standard
equations for rodents (as recommended by VisualSonics,
Bothell, WA). Matched baseline and ﬁnal echo data were
available for 9 mice in the WHC+placebo group, 9 in the
WHC+hArg group, 5 in WHC-eTNAP+placebo group, and 6 in
the WHC-eTNAP+hArg group.
Collection of Plasma and Tissues
Heparin plasma was prepared from venous blood collected
from the right ventricle of anesthetized mice. Mice were
fasted at least 5 hours before blood collection. Following
blood collection, whole-body perfusion with 10% formalin was
performed, and tissues were stored in 10% formalin until
dissection.
Blood Chemistry
Alkaline phosphatase, total cholesterol, triglycerides, inor-
ganic phosphate, and calcium were determined using speciﬁc
reagents (Pointe Scientiﬁc, Canton, MI). Lipemic plasma
samples were cleared with an equal volume of StatSpin
LipoClear reagent (Beckman Coulter, Brea, CA) before inor-
ganic phosphate and calcium determination. All samples were
analyzed using manual protocols and a plate reader (BioTek
Instruments, Winooski, VT). Measurements of L-homoarginine
were conducted by liquid chromatography–tandem mass
spectrometry according to a previously described proce-
dure.33,34 Pyridoxal phosphate was measured by liquid
chromatography–tandem mass spectrometry according to
the method adapted from Roelofsen-de Beer et al.35
Histology
Tissues were embedded in Optimal Cutting Temperature
compound and cryosectioned at 10 lm. Serial sections were
mounted on replica slides. For the aortic root samples, we
collected 72 consecutive sections on 8 slides. For the
midventricular slices of the heart, 36 sections were mounted
on 6 slides.
To detect calcium, sections were rehydrated in water,
stained in 2% alizarin red S (CI 58005) solution, pH 4.2, for
3 minutes, rinsed in distilled water followed by 3 changes of
phosphate-buffered saline, pH 7.4. Slides were then air-
dried and mounted in Clearium Mounting Medium (Leica,
Wetzlar, Germany). Another set of slides was rehydrated in
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water, rinsed in 60% isopropanol, and stained in 0.2% oil red
O (CI 26125) solution in 60% isopropanol for 15 minutes for
the detection of lipids. Following oil red O staining, slides
were rinsed in 60% isopropanol and 3 changes of tap water
and mounted in glycerin jelly mounting medium (Poly
Scientiﬁc, Bay Shore, NY). Picrosirius red staining was used
to detect collagen according to a published protocol for
cryosections.36
Tissues for histological analyses were extracted from 6
mice in the WHC+placebo group, 6 mice in the WHC+hArg
group, 5 mice in WHC-eTNAP+placebo group, and 6 mice in
the WHC-eTNAP+hArg group.
Morphometric Analysis
Morphometric analysis of alizarin red, oil red O, and
picrosirius red staining was performed using ImageJ.37
Regions of interest representing the left anterior descending
coronary artery (LAD), the septal artery, the aortic sinus, and
the left ventricle were manually outlined. Areas outside of
the regions of interest were cleared, and the resulting
images were sampled for colors representing positively
stained areas by visual inspection using the “adjust color
threshold” function of ImageJ. The areas above the set color
threshold were deﬁned as positive regions of interest and
recorded. Aortic root sections (6-8 per sample) were used to
measure calcium and lipids in the septal artery and plaques
in the aortic root. Mid-LV sections at the level of papillary
muscles (4-6 per sample) were used to measure calcium and
lipids in the LAD. Mid-LV sections were also used to
measure picrosirius red–positive regions representing colla-
gen. Picrosirius red–positive areas were quantiﬁed over the
entire LV cross section and expressed as percentage of
area.
Statistical Analyses
Statistical analyses were performed in GraphPad Prism 8
(GraphPad Software, San Diego, CA). Survival fractions and
curves were compared using Chi-square and Gehan-Breslow-
Wilcoxon tests, respectively. All other parameters were ﬁrst
tested for equality of variances using the Brown-Forsythe
method. The parametric variables were then compared using
ANOVA followed by Holm-Sidak multiple comparisons of
prespeciﬁed groups. The nonparametric variables were ana-
lyzed using a Kruskal-Wallis test followed by prespeciﬁed Dunn
multiple comparisons. The prespeciﬁed primary comparisons
were formulated to test (1) the effect of TNAP on the ﬁnal
outcomes by comparing the WHC+placebo and WHC-eTNAP+-
placebo groups, (2) the effect of hArg in the absence of coronary
artery disease (CAD) by comparing the WHC+placebo and
Table 1. Survival
WHC+
Placebo
WHC+
hArg
WHC-eTNAP
+Placebo
WHC-eTNAP
+hArg
N 16 10 23 16
Survival 93.75% 90.00% 21.74% * 37.50%
Median survival, d >42† >42† 27 33‡
eTNAP indicates overexpression of tissue-nonspeciﬁc alkaline phosphatase in the
endothelium; hArg, homoarginine; WHC, wicked high-cholesterol allele.
*P<0.0001 vs WHC+placebo by Chi-squared test.
†Undetermined.
‡Not signiﬁcant (P=0.10 vs WHC-eTNAP+placebo by Gehan-Breslow-Wilcoxon test).
Figure 1. Survival data and plasma homoarginine (hArg) levels.
A, Survival was monitored over 6 weeks starting at 6 weeks of
age. B, Homoarginine was measured in heparin plasma in a
subset of mice, ***P<0.001 vs placebo. eTNAP indicates
overexpression of tissue-nonspeciﬁc alkaline phosphatase in the
endothelium; WHC, wicked high-cholesterol allele.
Figure 2. Effect of hArg on alkaline phosphatase activity and
the levels of endogenous TNAP substrate pyridoxal phosphate
(PLP). A, Alkaline phosphatase activity was measured in heparin
plasma in a subset of mice, **P<0.01. B, Plasma levels of PLP, an
endogenous substrate of TNAP, *P<0.05. eTNAP indicates
overexpression of tissue-nonspeciﬁc alkaline phosphatase in the
endothelium; hArg, homoarginine; TNAP, tissue-nonspeciﬁc alka-
line phosphatase; WHC, wicked high-cholesterol allele.
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Figure 3. Effects of TNAP overexpression, an atherogenic diet, and hArg supplementation on plasma
inorganic phosphate, calcium, body weight, and plasma lipids (cholesterol and triglycerides). A, Plasma
inorganic phosphate, ***P<0.001. B, Plasma calcium. C, Body weight (BW), *P<0.05, ***P<0.001. D,
Plasma total cholesterol, *P<0.05, ***P<0.001. E, Plasma triglycerides, ****P<0.0001. F, Linear regression
analysis of the correlation between the duration of an atherogenic diet and plasma lipids in WHC-eTNAP
mice; open symbols represent early time points added to construct the correlation curves. BW indicates body
weight; eTNAP, overexpression of tissue-nonspeciﬁc alkaline phosphatase in the endothelium; hArg,
homoarginine; TNAP, tissue-nonspeciﬁc alkaline phosphatase; WHC, wicked high-cholesterol allele.
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WHC+hArg groups, and (3) the effect of hArg in mice with CAD
by comparing theWHC-eTNAP+placebo andWHC-eTNAP+hArg
groups. The percentage change from baseline was calculated
for all reported echocardiographic parameters and compared
between the groups by ANOVA or Kruskal-Wallis methods as
described above. Secondary analyses were performed to
compare body weight and plasma parameters (inorganic
phosphate, calcium, total cholesterol, triglycerides) between
the WHC and WHC-eTNAP groups at baseline and to determine
the effect of an atherogenic diet on these measures in each
group (WHC, WHC-eTNAP). In addition, a linear regression was
calculated to determine the effect of the duration of an
atherogenic diet on plasma lipids in WHC-eTNAP mice (the
placebo group). Statistical signiﬁcance was accepted at
P<0.05. Data are reported as meanSD.
Results
Homoarginine Supplementation and Survival in a
CAD Model
WHC-eTNAP mice had signiﬁcantly reduced survival under
the atherogenic conditions of our experiment compared with
WHC mice (21.7% versus 93.8%, P<0.0001, Table 1 and
Figure 1A) as was expected.24 The median survival in the
WHC-eTNAP+placebo group was 27 days. The WHC-eTNA-
P+hArg group showed a 37.5% survival under conditions of
our study with the median survival of 33 days (Table 1 and
Figure 1A). To verify if our supplementation protocol indeed
increased hArg levels, we measured hArg concentrations in
plasma. Plasma levels of hArg were increased 3-fold in
hArg-supplemented mice compared with mice given the
Figure 4. Alizarin red staining for calcium. A, Left anterior descending artery (LAD, top panels), proximal
segment of the septal artery (middle panels), and the aortic root (bottom panels). B through D,Morphometric
quantiﬁcation of alizarin red positive area in the LAD (B), septal artery (C), and the aortic root (D). *P<0.05,
***P<0.001. eTNAP indicates overexpression of tissue-nonspeciﬁc alkaline phosphatase in the endothelium;
hArg, homoarginine; LAD, left anterior descending artery; WHC, wicked high-cholesterol allele.
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placebo treatment in both comparisons, with and without
TNAP overexpression (Figure 1B, P<0.001).
Homoarginine Supplementation Did Not Inﬂuence
Alkaline Phosphatase Activity
Homoarginine supplementation inﬂuenced neither alkaline
phosphatase activity in plasma (Figure 2A) nor systemic levels
of pyridoxal phosphate, which can be regarded as a marker of
changes in alkaline phosphatase activity in vivo38 (Figure 2B).
Homoarginine Supplementation, Body Weight,
and Plasma Parameters in Mice With CAD
Plasma inorganic phosphate was elevated in the WHC+pla-
cebo group compared with baseline (P<0.001, Figure 3A),
whereas in the WHC+hArg group this effect was insigniﬁcant.
Plasma calcium appeared to be suppressed in mice on an
atherogenic diet, but this reduction was insigniﬁcant in 2
prespeciﬁed comparisons (WHC+placebo versus WHC base-
line and WHC-eTNAP+placebo versus WHC-eTNAP baseline,
Figure 3B). There were no differences in plasma inorganic
phosphate or calcium between the placebo- and hArg-treated
groups (Figure 3A and 3B).
There was a signiﬁcant increase in body weight (BW) in the
WHC+placebo group as compared with baseline (P<0.05).
WHC-eTNAP+placebo mice were signiﬁcantly lighter than
WHC+placebo mice at the end of the study (P<0.001,
Figure 3C). Compared with baseline, plasma cholesterol was
higher in the WHC+placebo (P<0.001) group but not in the
WHC-eTNAP+placebo group (Figure 3D). There was an 50%
increase in total plasma cholesterol in WHC-eTNAP mice
Figure 5. Oil red O staining for lipids. A, Left anterior descending artery (LAD, top panels), proximal
segment of the septal artery (middle panels), and the aortic root (bottom panels). B through D,
Morphometric quantiﬁcation of oil red O—positive areas in the LAD (B), septal artery (C), and the aortic root
(D), *P<0.05, ***P<0.001. eTNAP indicates overexpression of tissue-nonspeciﬁc alkaline phosphatase in the
endothelium; hArg, homoarginine; LAD, left anterior descending artery; WHC, wicked high-cholesterol allele.
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receiving hArg compared with placebo (P<0.05, Figure 3D).
Similarly to cholesterol, triglycerides were elevated in the
WHC+placebo group (P<0.0001) but not in the WHC-eTNAP+
placebo group compared with baseline (Figure 3E). The effects
of hArg on triglycerideswere not signiﬁcant in either theWHCor
the WHC-eTNAP group compared with the corresponding
placebo groups (Figure 3E). Further examination of plasma
lipids in WHC-eTNAP+placebo mice with the addition of 2
samples collected at the earlier time points (8 and 13 days after
initiation of an atherogenic diet, Figure 3F, open symbols)
showed a gradual decline in plasma triglycerides (P<0.05) and a
nonsigniﬁcant trend for the reduction of cholesterol in WHC-
eTNAP+placebo mice over time (P=0.051, linear regression,
Figure 3F).
Table 2. Echocardiography
WHC+Placebo WHC+hArg WHC-eTNAP+Placebo WHC-eTNAP+hArg
N 9 9 5 6
Age, wk
Baseline 6.20.3 6.00.2 6.10.3 6.20.4
Final 11.20.5 110.2 10.30.4† 10.70.6
BW, g
Baseline 21.21.2 21.81.8 20.51.4 21.61.2
Final 24.13.9 24.41.7 17.11.7* 17.32.3
HR, bpm
Baseline 46160 40646 42927 4037
Final 43162 46144 32584 371128
LVPWd/BW, mm/g
Baseline 0.0360.007 0.0330.007 0.0320.004 0.0330.006
Final 0.0340.007 0.030.005 0.0590.028 0.0570.013
IVSd/BW, mm/g
Baseline 0.0360.003 0.0340.007 0.0410.011 0.0360.005
Final 0.0360.005 0.0320.004 0.0550.027 0.0630.008
LVIDd/BW, mm/g
Baseline 0.170.02 0.170.02 0.190.03 0.190.02
Final 0.150.02 0.160.01 0.250.07‡ 0.180.05k
LV mass/BW, mg/g
Baseline 3.450.54 3.320.62 4.001.13 4.150.47
Final 3.60.75 3.260.44 8.043.7* 4.920.47§
FS, %
Baseline 37.210.9 29.46.3 30.811.6 30.29.2
Final 30.99.9 24.36 20.46.2* 34.08.2§
EF, %
Baseline 71.914.3 62.49.6 62.815 6313.4
Final 63.913.8 54.310.4 46.812.5* 69.212§
CO/BW, lL/min per g
Baseline 0.710.17 0.600.12 0.760.17 0.850.21
Final 0.570.16 0.560.1 0.750.44 0.440.28
Data are expressed as meanSD. BW indicates body weight; CO, cardiac output; EF, ejection fraction; eTNAP, overexpression of tissue-nonspeciﬁc alkaline phosphatase in the
endothelium; FS, fractional shortening; hArg, homoarginine; HR, heart rate; IVSd, interventricular septum thickness in diastole; LVIDd, left ventricular end diastolic diameter; LVmass, left
ventricular mass; LVPWd, left ventricular posterior wall thickness in diastole; WHC, wicked high-cholesterol allele.
*P<0.05, †P<0.01, ‡P<0.01 vs WHC+placebo.
§P<0.05, kP<0.01 vs WHC-eTNAP+placebo.
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Homoarginine Supplementation Did Not Inﬂuence
Calciﬁcation and Lipid Deposition in Coronary
Arteries or Aortic Root
Consistent with our previous observations,24 endothelial TNAP
overexpression resulted in increased calciﬁcation of the LAD
(P<0.001) and atherosclerotic plaques in the aortic root inWHC-
eTNAP mice (P<0.05, Figure 4). Contrary to our hypothesis,
however, hArg supplementation led to no signiﬁcant changes in
calcium in any of the 3 vascular segments tested (Figure 4).
TNAP overexpression resulted in an increase in coronary
lipid deposition (LAD, P<0.001, Figure 5B) and a decrease in
the size of atherosclerotic plaques in the aortic root of WHC-
eTNAP mice compared with WHC (P<0.05, Figure 5D). hArg
supplementation did not inﬂuence the amount of lipids
deposited in the LAD, the septal branch of coronary arteries,
or the aortic root as quantiﬁed by oil red O staining (Figure 5).
Protective Effects of Homoarginine on the
Myocardium
Unable to detect an inhibitory effect of hArg on the
calciﬁcation-promoting activity of TNAP, we next investigated
if the protective action of hArg in the setting of calciﬁed CAD
could be mediated by its effects on the myocardial structure
and function.
WHC-eTNAP mice were characterized by reduced BW
(P<0.05), increased LV diameter (per BW, P<0.0001), LV
mass index (LVmass/BW, P<0.05), and reduced LV frac-
tional shortening (P<0.05) and ejection fraction (P<0.05)
compared with WHC (Table 2). Supplementation of WHC-
eTNAP mice with hArg prevented LV dilatation (per BW,
P<0.01), reduced LV hypertrophy (LVmass/BW, P<0.05),
and preserved LV fractional shortening and ejection fraction
(P<0.05, Table 2).
Analyzing echocardiographic changes from baseline, we
found that WHC-eTNAP+placebo mice experienced a 33% (0%,
66%) increase in the LV diameter (per BW), whereas WHC-
eTNAP mice treated with hArg showed a small 8% (14%,
3%) reduction in the LV diameter (P<0.001, Figure 6A and
6B). hArg also reversed a negative change in fractional
shortening from a 30% (57%, 3%) reduction in the
placebo group to a 19% (21%, 58%) increase in hArg-treated
WHC-eTNAP mice (P<0.05, Figure 6C). Likewise, hArg
reversed the effect on the ejection fraction in WHC-eTNAP
mice from a 25% (47%, 2%) reduction in the placebo
Figure 6. Echocardiographic data. A, M-mode echocardiographic images of the left. B, LVIDd normalized
to body weight, change from baseline. C, Fractional shortening, change from baseline. D, Ejection fraction,
change from baseline. *P<0.5, **P<0.01, ***P<0.001, ****P<0.0001. BW indicates body weight; eTNAP,
overexpression of tissue-nonspeciﬁc alkaline phosphatase in the endothelium; hArg, homoarginine; LVIDd,
left ventricular internal diameter in diastole (left ventricular end-diastolic diameter); WHC, wicked high-
cholesterol allele.
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group to a 13% (15%, 41%) increase in the hArg group
(P<0.05, Figure 6D).
LV collagen content (measured by picrosirius red staining)
was increased in WHC-eTNAP+placebo mice compared with
WHC+placebo (P<0.0001, Figure 7). Treatment of WHC-
eTNAP mice with hArg reduced myocardial collagen deposi-
tion compared with the placebo treated group (P<0.01,
Figure 7).
Discussion
Contrary to our mechanistic hypothesis regarding the effects
of hArg on TNAP activity and coronary calciﬁcation as a
possible explanation for cardioprotective properties of this
molecule in vivo, we found no evidence that hArg inhibits
TNAP activity or reduces coronary calciﬁcation or atheroscle-
rosis (Figures 1 through 3). Interestingly, however, hArg
treatment was associated with protection from LV dilatation
on the background of severe dyslipidemia and coronary artery
disease (Figures 3, 6, and 7, Table 2) and a modest improve-
ment in survival (Figure 1 and Table 1).
Low hArg levels predict an adverse outcome in multiple
cardiovascular, metabolic, and renal pathologies; however, it
is still not entirely clear whether hArg plays a direct protective
role in at least some of those pathologies. Our ﬁnding that
dietary hArg supplementation improved outcomes in an
experimental model of coronary atherosclerosis and heart
failure supports the hypothesis that hArg is more than just a
marker and can have direct protective cardiovascular effects.
This observation is in line with the previous studies, demon-
strating direct protective effects of homoarginine in experi-
mental cardiovascular and metabolic models.12,16-18
We hypothesized that protection might be mediated
through the hArg effect on calciﬁcation, based on its ability
to inhibit TNAP activity in vitro.23,24 At least in our
experimental model we could not detect any inhibitory effect
of hArg on TNAP activity or vascular calciﬁcation in vivo, as
evidenced by a lack of changes in alkaline phosphatase
Figure 7. Picrosirius red staining for collagen. A, Representative images of picrosirius red–stained sections through the left ventricle (LV) of
the heart. B, Representative high-resolution images corresponding to the insets in (A). C, Morphometric quantiﬁcation of collagen (percentage
picrosirius red–positive area relative to the total LV area), **P<0.01, ****P<0.0001. eTNAP indicates overexpression of tissue-nonspeciﬁc
alkaline phosphatase in the endothelium; hArg, homoarginine; WHC, wicked high-cholesterol allele.
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activity and pyridoxal phosphate levels in plasma and a lack of
protective effect of hArg on coronary calciﬁcation. Overall, our
ﬁndings in this model of coronary artery disease suggest that
hArg improved the disease course through a mechanism that
is independent of vascular calciﬁcation. A lack of hArg effects
on vascular calciﬁcation in our study is consistent with the
report by Alesutan and colleagues, who observed augmented
vascular calciﬁcation in response to hArg treatment in
hyperphosphatemic klotho-hypomorphic mice, in mice with
renal failure, and in mice after vitamin D3 overload.
39 A lack of
association between low plasma hArg and coronary calciﬁca-
tion was also observed in the population-based Dallas Heart
Study.15 On the other hand, it was shown that L-lysine, a hArg
precursor, prevented arterial calciﬁcation in adenine-induced
uremic rats, whereas hArg inhibited precipitation of minerals
in vitro in a solution of supersaturated calcium/phosphate.40
However, the same study by Shimomura also suggested
several potential hArg-independent mechanisms for L-lysine to
affect vascular calciﬁcation, and the physiologic relevance of
the effect of hArg on precipitation of calcium phosphate
in vitro is currently unclear.
Our study did not show any protective effects of hArg on
coronary atherosclerosis in WHC-eTNAP mice on the Paigen
diet. This ﬁnding is consistent with the lack of association
between low hArg levels and aortic plaques in the Dallas Heart
Study15 and suggests that hArg might not have a major effect
on atherosclerosis progression. The effect of hArg on
coronary atherosclerosis in WHC-eTNAP mice might have
been masked by the restoration of hypercholesterolemia to
the levels observed in WHC mice. It also must be noted that
our model, although it recapitulates the genetics and lipid
abnormalities of familial hypercholesterolemia,41-43 is not the
classical experimental model of atherosclerosis. We therefore
suggest that the effect of hArg on atherosclerosis progression
will need to be systematically addressed in models that are
more appropriate for this study question, such as apoE
knockout and Ldlr knockout mice.
The key ﬁnding of our study is that hArg mediated
protection from LV dilatation and preserved LV ejection
fraction. Our data are consistent with the recent reports that
hArg supplementation improved cardiac contractile function
in a murine model of post–myocardial infarction heart
failure.16 Furthermore, impaired cardiac contractile reserve
in arginine:glycine amidinotransferase knockout mice with low
creatine and hArg levels was rescued not by creatine
supplementation but by hArg supplementation.17 Bahls and
colleagues recently reported a correlation between low
plasma hArg and decreased LV function in a large cohort of
3113 subjects, suggesting that the protective effects of hArg
on myocardial contractility that were observed in animal
models might also be relevant for humans.44 Our character-
izations of the positive effects of hArg on LV geometry are
also consistent with the reported association between hArg
and LV dilatation.44 The mechanisms underlying this direct
effect of hArg on LV remodeling are still unclear and need to
be addressed in future studies.
The study presented here is limited to male mice and was
conducted at extremely high levels of dyslipidemia as well as
artiﬁcially increased levels of plasma alkaline phosphatase.
The study was focused on the heart and has not yet
considered the effect of hArg on other organ systems under
conditions of coronary artery disease and/or heart failure.
In summary, our study further supports the hypothesis that
hArg not only is a risk assessment marker but also has direct
protective cardiovascular and metabolic effects. Speciﬁcally,
we observed direct protective effects of hArg on myocardial
remodeling. Daily oral supplementation with 125 mg hArg in
capsules increased its plasma levels severalfold in healthy
volunteers without causing any detectable side effects.20,32
This identiﬁes hArg supplementation as a well-tolerated and
nonharmful treatment that can be further tested in phase 2
and phase 3 clinical studies for improvement of cardiovascu-
lar outcome in patients at risk. Based on our results and the
results by others, patients with heart failure might be a patient
population with especially high chances to beneﬁt from hArg
supplementation.
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